Pohunek, Petr http://orcid.org/0000-0003-4557-2515
Varoli, Guido
Reznichenko, Yuriy
Mokia-Serbina, Svetlana
Brzostek, Jerzy
Kostromina, Viktoriya
Kaladze, Mykola
Muraro, Annamaria
Carzana, Elena
Armani, Silvia
Kaczmarek, Jadwiga
Funding for this research was provided by:
Chiesi Farmaceutici
Article History
Received: 6 November 2020
Revised: 6 November 2020
Accepted: 20 November 2020
First Online: 6 January 2021
Compliance with ethical standards
:
: Yuriy Reznichenko, Svetlana Mokia-Serbina, Jerzy Brzostek, Viktoriya Kostromina, Mykola Kaladze, and Jadwiga Kaczmarek all received clinical research funds from Chiesi Farmaceutici S.p.A. as site investigators for this study. Petr Pohunek received funds from Chiesi Farmaceutici S.p.A. as Scientific Coordinating Investigator of the study, lecturer fee from Novartis, TEVA, AstraZeneca and travel grant from Novartis and is a member of the advisory boards of Novartis and GlaxoSmithKline. Guido Varoli, Annamaria Muraro, Elena Carzana, and Silvia Armani are full employees of Chiesi Farmaceutici S.p.A., sponsor of the study.
: The regulatory authorities in each participating country and Ethical Review boards for each institution and prior to registration (ExternalRef removed ID: NCT01584492) approved the study.
: Each patient, parents and/or legal guardian provided with the written informed consent prior to study entry.
: All the authors were involved in the review and editing of the draft manuscript and provided their approval of the final version of the manuscript and consent for its publication.